STERIS plc (NYSE: STE) is a Healthcare company in the Medical - Specialties industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 29.36 | EPS (ttm) | 7.93 | Insider Own | 0.45% | Shs Outstand | 97.46M | Perf Week | 1.09% |
| Market Cap | 22.69B | Forward P/E | 19.11 | EPS next Y | 12.18 | Insider Trans | -2.39% | Shs Float | 97.13M | Perf Month | 9.18% |
| Enterprise Value | 24.34B | PEG | 3.35 | EPS next Q | - | Inst Own | - | Short Float | 2.51% | Perf Quarter | 9.71% |
| Income | 782.00M | P/S | 3.82 | EPS this Y | 40.69% | Inst Trans | - | Short Ratio | 2.97 | Perf Half Y | -11.88% |
| Sales | 5.93B | P/B | 3.15 | EPS next Y | 9.19% | ROA | 7.29% | Short Interest | 2.44M | Perf YTD | -8.15% |
| Book/sh | 73.85 | P/C | 51.57 | EPS next 5Y | 8.77% | ROE | 11.05% | 52W High | 269.44 -13.58% | Perf Year | 2.64% |
| Cash/sh | 4.51 | P/FCF | 22.89 | EPS past 3/5Y | 94.97% 11.36% | ROIC | 8.47% | 52W Low | 195.15 19.32% | Perf 3Y | 1.22% |
| Dividend Est. | 2.76 (1.19%) | EV/EBITDA | 13.32 | Sales past 3/5Y | 9.38% 13.82% | Gross Margin | 44.25% | Volatility | 2.16% 2.42% | Perf 5Y | 8.37% |
| Dividend TTM | 2.52 (1.08%) | EV/Sales | 4.10 | EPS Y/Y TTM | 27.90% | Oper. Margin | 18.56% | ATR (14) | 5.85 | Perf 10Y | 241.22% |
| Dividend Ex-Date | Sep 04, 2026 | Quick Ratio | 1.54 | Sales Y/Y TTM | 8.70% | Profit Margin | 13.18% | RSI (14) | 63.76 | Recom | 2.15 |
| Dividend Gr. 3/5Y | 10.06% 9.28% | Current Ratio | 2.09 | EPS Q/Q | 21.98% | SMA20 | 6.13% | Beta | 0.91 | Target Price | 271.33 |
| Payout | 30.90% | Debt/Eq | 0.29 | Sales Q/Q | 7.22% | SMA50 | 8.83% | Rel Volume | 1.08 | Prev Close | 232.64 |
| Employees | 17,937 | LT Debt/Eq | 0.27 | Earnings | Aug 05 | SMA200 | -0.70% | Avg Volume | 829.38K | Price | 232.85 |
| IPO Date | Jun 01, 1992 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -0.65% -0.39% | Net Debt/EBITDA | 0.90 | Volume | 898,618 | Change | 0.09% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-28-26 | Initiated | UBS | Buy | $275 |
| May-21-26 | Reiterated | Piper Sandler | Overweight | $260 → $270 |
| May-13-26 | Reiterated | Keybanc | Overweight | $265 → $269 |
| Jul-15-25 | Upgrade | Morgan Stanley | Equal Weight → Overweight | |
| Oct-24-24 | Upgrade | Piper Sandler | Neutral → Overweight | $225 → $260 |
| Sep-03-24 | Reiterated | KeyBanc | Overweight | $255 → $265 |
| May-10-24 | Reiterated | Piper Sandler | Neutral | $225 |
| Apr-04-24 | Reiterated | Wolfe Research | $245 | |
| Apr-14-23 | Downgrade | Piper Sandler | Overweight → Neutral | |
| Sep-23-22 | Downgrade | Needham | Buy → Hold |
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2026 3/31/2026 | FY 2025 3/31/2025 | FY 2024 3/31/2024 | FY 2023 3/31/2023 | FY 2022 3/31/2022 | FY 2021 3/31/2021 | FY 2020 3/31/2020 | FY 2019 3/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5,935 | 5,936 | 5,460 | 5,139 | 4,536 | 4,223 | 3,108 | 3,031 | 2,782 | |
| Cost of Goods Sold Incl. D&A | 3,309 | 3,309 | 3,057 | 2,921 | 2,556 | 2,340 | 1,764 | 1,711 | 1,607 | |
| Gross Profit | 2,627 | 2,627 | 2,403 | 2,218 | 1,981 | 1,883 | 1,343 | 1,320 | 1,175 | |
| Selling, General and Administrative Excl. Other | 1,408 | 1,408 | 1,334 | 1,252 | 1,091 | 1,318 | 731 | 717 | 670 | |
| Research and Development | 113 | 113 | 108 | 104 | 98 | 87 | 66 | 66 | 63 | |
| Other Operating Expense | 4 | 4 | 94 | 26 | 1 | 0 | -2 | 0 | 31 | |
| Operating Income | 1,102 | 1,102 | 867 | 836 | 791 | 478 | 548 | 537 | 411 | |
| Interest Expense | 61 | 61 | 86 | 144 | 111 | 89 | 37 | 40 | 45 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 7 | 6 | 16 | 11 | 0 | -22 | 6 | 2 | 3 | |
| Net Income Before Taxes | 1,048 | 1,047 | 796 | 703 | 680 | 367 | 518 | 499 | 369 | |
| Income Taxes | 263 | 262 | 185 | 150 | 124 | 82 | 121 | 91 | 64 | |
| Consolidated Net Income | 782 | 785 | 615 | 378 | 107 | 244 | 397 | 408 | 304 | |
| Net Income From Continuing Operations | 785 | 785 | 612 | 553 | 556 | 284 | 397 | 408 | 305 | |
| Net Income | 782 | 785 | 615 | 378 | 107 | 244 | 397 | 408 | 304 | |
| EPS (Recurring) | 7.95 | 7.93 | 6.24 | 3.83 | 1.07 | 2.50 | 4.66 | 4.81 | 3.59 | |
| EPS (Basic, Before Extraordinaries) | 7.95 | 7.93 | 6.24 | 3.83 | 1.07 | 2.50 | 4.66 | 4.81 | 3.59 | |
| EPS (Diluted) | 7.93 | 7.93 | 6.20 | 3.81 | 1.07 | 2.48 | 4.63 | 4.76 | 3.56 | |
| EBITDA | 1,828 | 1,595 | 1,359 | 1,412 | 1,235 | 1,009 | 774 | 736 | 640 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 29.36 | 27.89 | 36.56 | 59.01 | 178.77 | 97.49 | 41.14 | 29.41 | 35.96 | |
| Price To Sales Ratio | 3.84 | 3.65 | 4.11 | 4.33 | 4.22 | 5.61 | 5.21 | 3.93 | 3.91 | |
| Gross Margin | 44.26 | 44.26 | 44.01 | 43.16 | 43.67 | 44.59 | 43.21 | 43.55 | 42.24 | |
| Operating Margin | 18.57 | 18.56 | 15.88 | 16.27 | 17.44 | 11.32 | 17.63 | 17.72 | 14.77 | |
| Net Margin | 13.18 | 13.22 | 11.26 | 7.36 | 2.36 | 5.78 | 12.77 | 13.46 | 10.93 | |
| Shares Outstanding | 98 | 98 | 99 | 99 | 100 | 98 | 85 | 85 | 85 | |
| Market Capitalization | 22,819 | 21,671 | 22,438 | 22,257 | 19,128 | 23,693 | 16,191 | 11,897 | 10,883 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Sohi Mohsen | Director | Jul 01 '26 | Option Exercise | 71.40 | 3,781 | 269,963 | 26,142 | Jul 02 |
| Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | Jun 15 '26 | Sale | 209.28 | 1,419 | 296,968 | 35,259 | Jun 16 |
| Carestio Daniel A | President and CEO | Jun 05 '26 | Sale | 212.00 | 1,374 | 291,288 | 63,647 | Jun 08 |
| Carestio Daniel A | President and CEO | Jun 04 '26 | Sale | 214.64 | 3,054 | 655,511 | 65,021 | Jun 08 |
| Burton Karen L | Sr. Vice Pres., CFO | Jun 02 '26 | Option Exercise | 209.76 | 66 | 13,844 | 13,464 | Jun 04 |
| Breeden Richard C | Director | Jun 02 '26 | Option Exercise | 71.40 | 3,781 | 269,963 | 40,445 | Jun 04 |
| Breeden Richard C | Director | Jun 02 '26 | Sale | 209.51 | 1,481 | 310,284 | 38,964 | Jun 04 |
| FELDMANN CYNTHIA L | Director | Mar 05 '26 | Option Exercise | 152.32 | 3,098 | 471,887 | 3,803 | Mar 06 |
| FELDMANN CYNTHIA L | Director | Mar 05 '26 | Sale | 237.21 | 3,098 | 734,877 | 705 | Mar 06 |
| Madsen Julia | Sr. VP and GM, Life Sciences | Nov 21 '25 | Sale | 262.00 | 2,136 | 559,632 | 10,710 | Nov 25 |
| Madsen Julia | Sr. VP and GM, Life Sciences | Nov 21 '25 | Option Exercise | 128.22 | 5,008 | 642,139 | 13,582 | Nov 25 |
| Tamaro Renato | V.P. & Corporate Treasurer | Nov 18 '25 | Sale | 257.55 | 5,036 | 1,297,039 | 5,695 | Nov 20 |
| Tamaro Renato | V.P. & Corporate Treasurer | Nov 18 '25 | Option Exercise | 182.22 | 3,536 | 644,330 | 10,731 | Nov 20 |
| Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | Nov 11 '25 | Sale | 265.14 | 15,000 | 3,977,100 | 33,669 | Nov 13 |
| Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | Nov 11 '25 | Option Exercise | 69.72 | 15,000 | 1,045,800 | 48,669 | Nov 13 |